Pfizer Inc. (NYSE:PFE) Declares $0.43 Quarterly Dividend

Pfizer Inc. (NYSE:PFE) announced a quarterly dividend on Friday, December 12th. Shareholders of record on Friday, January 23rd will be given a dividend of 0.43 per share by the biopharmaceutical company on Friday, March 6th. This represents a c) dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd.

Pfizer has increased its dividend by an average of 0.0%per year over the last three years and has increased its dividend annually for the last 16 consecutive years. Pfizer has a payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $3.03 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 56.8%.

Pfizer Trading Down 0.5%

NYSE PFE opened at $25.52 on Wednesday. The company has a market cap of $145.07 billion, a price-to-earnings ratio of 14.83 and a beta of 0.47. Pfizer has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The business’s fifty day moving average is $25.38 and its 200 day moving average is $24.99.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PFE shares. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Morgan Stanley reduced their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Finally, Bank of America dropped their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $27.88.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.